All News
![](https://pbs.twimg.com/media/GE4DbtMXUAAWzd0.png)
#RNL2024 @RheumNow
Winthrop on Shingrix:
Good data at 10 yrs
Diminished response in immunocompromised (chemo)
Very limited data with autoimmune patients https://t.co/cJitGOWZQt
Eric Dein ericdeinmd ( View Tweet)
![](https://pbs.twimg.com/media/GE4C5QcWwAAy2r7.jpg)
The 10 year Shingrix data showing continued humoral responses in "normal" patients, with continued long-term efficacy (drops to only 70+%) suggesting we may need to boost at some point.
In our rheumatology patients, the efficacy does drop and needs to be evaluated. Dr. Kevin… https://t.co/eHfjtsPv2O https://t.co/K1i5R3ZScV
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
![](https://pbs.twimg.com/media/GE4ChhqXwAAYuca.png)
@RheumNow #RNL2024
Winthrop:
JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies
Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R
Links:
Eric Dein ericdeinmd ( View Tweet)
![](https://pbs.twimg.com/media/GE38l2FXIAAvcDU.jpg)
So why should you consider JAKi?
Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety.
#RNL2024 @RheumNow https://t.co/BgFjhb18Ad
Dr. Rachel Tate uptoTate ( View Tweet)
![](https://pbs.twimg.com/media/GE319XWXIAAEMSy.jpg)
Random effect in ACR20 responses in male versus females in PsA.
No sex differences in ACR20 responses in patients on JAK/TYK2i .
@lihi_eder
#RNL2024
@RheumNow https://t.co/fgEORm0nKc
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE32HrVWMAAPpZT.jpg)
Sex/Gender disparities in rheumatology.
@lihi_eder
#RNL2024
@RheumNow https://t.co/PB7zPYJHd0
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE32h7aX0AAjxU4.jpg)
A word on Explicit/ Implicit Bias .
Amazing talk and very insightful.
@lihi_eder
#RNL2024
@RheumNow https://t.co/SGmk5wa9nP
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE362vJXsAAaFNc.jpg)
JAKi toxicities of interest:
- Zoster
- Safety: VTE, MACE, Malignancies
- Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias.
@JointMD #RNL2024
@rheumnow https://t.co/u72yz8uLYB
Dr. Rachel Tate uptoTate ( View Tweet)
![](https://pbs.twimg.com/media/GE33263XMAAI6s5.jpg)
@JointMD reviews the pros and cons of JAKi at #RNL2024 @RheumNow https://t.co/z9CSvP5BAZ
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
![](https://pbs.twimg.com/media/GE30RRhXsAAjZ9k.jpg)
More evidence to support role of Tyk2 in management
of skin psoriasis.
Dr.April Armstrong
#RNL2024
@RheumNow https://t.co/9vuuhJMj36
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE30lVCWUAA3g_-.jpg)
Amazing talk by @lihi_eder on sex differences in PsA.
#RNL2024
@RheumNow https://t.co/PW5fYLYmu5
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE3z8MoWoAAxKin.jpg)
Crossed out all therapies that doesn’t work for skin psoriasis.
For some reason, i thought that JAKi s worked for skin psoriasis. Thanks to Dr.Armstrong for clarifying.
#RNL2024
@RheumNow https://t.co/f71qmHGLwm
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE3zOrfXoAAnK58.jpg)
FDA-approved biologics for skin psoriasis by April Armstrong , its always nice to hear from Derm colleagues.
#RNL2024
@RheumNow https://t.co/vTLpOim8Ct
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE3y1Y7XkAA9eNN.jpg)
Impact of obesity on PsA @AlexisOgdie
Weight loss works in PsA:
5 to 10% weight loss lead to OR: 3.7 MDA responses
> 10% of body weight lead even higher odds ( 6.67). #RNL2024
@RheumNow https://t.co/73O0I7uZF4
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/media/GE3xTojWYAAM6QR.jpg)
Sever psoriatic arthritis / psoriasis by @AlexisOgdie
#RNL2024
@RheumNow https://t.co/KbN7mnHTSd
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
![](https://pbs.twimg.com/profile_images/1351717401415573513/Za85Ytpr_normal.jpg)
Treating dactylitis and enthesitis: this is a sign of aggressive disease. Dr. @AlexisOgdie will treat with high dose NSAIDS and get patients on biologics quickly. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
![](https://pbs.twimg.com/profile_images/1351717401415573513/Za85Ytpr_normal.jpg)
Which IL17i to choose? Depends on the domain
Dr. Armstrong: For the skin, the studies show brodalumab, ixekizumab and bimekizumab are superior to secukimumab for #psoriasis
Dr. @AlexisOgdie noted we don't see much differences in these IL17i for the joints.
#RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
![](https://pbs.twimg.com/media/GE1DhKfWkAE8iXs.jpg)
The differences do appear to relate to actual treatment specific differential response. As well as no difference with JAKi, there seems to be no difference in placebo response @lihi_eder @RheumNow #RNL2024 https://t.co/7H4KRvd6WG
Richard Conway RichardPAConway ( View Tweet)
![](https://pbs.twimg.com/media/GE1DSx3W0AAInbm.jpg)
Many advanced treatments appear to work less well in female patients with PsA, but JAKi seem to not demonstrate this phenomenon. Not sure what to do with this data in clinical practice but it is certainly intriguing @lihi_eder @RheumNow #RNL2024 https://t.co/GDrg715ctg
Richard Conway RichardPAConway ( View Tweet)
![](https://pbs.twimg.com/media/GE3iIh7XIAAYWST.jpg)
@AlexisOgdie @_AprilArmstrong @lihi_eder are the amazing “Hot topics in PsA” panelists. #RNL2024 @RheumNow #womenforthewin https://t.co/6V2QyGJM98
Dr. Rachel Tate uptoTate ( View Tweet)